Greg Crescenzi

Greg is the Chief Executive Officer at Nirrin. Prior to Nirrin, Greg led the MIT spinout Kytopen as its Chief Commercial Officer responsible for driving commercial strategy to accelerate its non-viral gene delivery platform. Greg also worked at Cytiva (formerly GE Healthcare Life Sciences) where he served as the Enterprise Delivery Leader for the Cell & Gene Therapy business helping to build out the Enterprise Solutions business. Here he also served as Business Leader for Cell Culture Services, Xcellerex and Microcarriers, launching flagship products and quadrupling revenue. Prior to joining GE Healthcare, he held business leadership, sales and marketing positions at BD Biosciences, Pall Life Sciences, and Millipore Corporation. Greg holds a Bachelor of Science in Chemical Engineering from Tufts University and an MBA from Boston University.